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Abstract
Aims: We aimed to analyze the relationship between epilepsy and glutamic acid
decarboxylase autoantibodies (GADA) in patients with type 1 diabetes mellitus
(T1DM) and the impact of GADA on demographic, clinical, and metabolic data in
T1DM patients with epilepsy.
Methods: We searched for patients with T1DM ≤20 years and GADA measure-
ments, and within this group for patients with epilepsy. We formed groups: T1DM
+ Epilepsy + GADA positive; T1DM + Epilepsy + GADA negative; T1DM + GADA
positive; T1DM + GADA negative. We used logistic regression to analyze the rela-
tionship between epilepsy and GADA with odds ratio adjusted for sex, duration of
diabetes (DOD), and age at diabetes onset (ADO). We used logistic regression with
odds ratio adjusted for DOD and ADO onset using epilepsy as a dependent variable
and GADA, HbA1c, ketoacidosis, severe hypoglycemia (SH), sex, celiac disease, and
autoimmune thyroiditis as independent variables. We conducted regression analyses
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adjusted for sex, DOD, and ADO to analyze differences in clinical/metabolic parame-
ters between the groups.
Results: Epilepsy was not more frequent in GADA-positive patients (GPP). Logistic
regression including all patients with GADA measurements showed that hypoglyce-
mia with coma (HC) correlated with epilepsy when compared to no SH. We found no
differences in clinical and metabolic data between GPP and GADA-negative patients
(GNP) with epilepsy. SH occurred more often in GPP with epilepsy in comparison to
GPP without epilepsy. GNP with epilepsy had a higher rate of HC than GPP without
epilepsy.
Conclusion: We found no relationship between epilepsy and GADA. A relationship
between T1DM and epilepsy might be explainable by SH.
K E YWORD S
children and adolescents, diabetes mellitus type 1, epilepsy, glutamic acid decarboxylase
autoantibodies, severe hypoglycemia
1 | INTRODUCTION
The pathogenesis of type 1 diabetes mellitus (T1DM) is characterized
by autoimmune destruction of beta cells in the pancreas.1 Being an
autoimmune disorder, T1DM is associated with other immune-
mediated diseases, such as autoimmune thyroid disease (AIT),2 celiac
disease,3,4 and Addison's disease,5 suggesting a common genetic
susceptibility.6
The relationship between T1DM and epilepsy remains a topic of
controversy although most evidence points toward an increased risk
of epilepsy for patients with T1DM.7-11 Factors considered to contrib-
ute to neuronal damage finally causing epilepsy in T1DM are immune-
mediated processes linked to the autoimmune pathogenesis of T1DM
itself including autoantibodies to glutamic acid decarboxylase autoan-
tibodies (GADA), metabolic abnormalities (hypo- and hyperglycemia),
cerebrovascular disease, and genetic risks. The exact mechanisms,
however, are not fully understood.12
GADA are directed against secretory vesicles in the pancreatic
islet cells and are proven to play an important pathogenic role in the
development of T1DM, contributing to the destruction of the insulin-
producing pancreatic cells.13 As for the central nervous system (CNS),
GADA are directed against the enzyme glutamic acid decarboxylase,
which is essential for the formation of the inhibitory neurotransmitter
gamma-aminobutyric acid (GABA). Among others, GADA have been
linked to autoimmune encephalitis, Stiff man syndrome, cerebellar
ataxia, and severe epilepsy particularly affecting the temporal lobe.14
This leads to the question of whether GADA might disturb inhibitory
GABA-mediated neurotransmission in the CNS and contribute to the
pathogenesis of epilepsy among patients with T1DM.15 So far, only
few studies have addressed this question. Aguiar et al studying
375 adults with T1DM found similar rates of GADA among patients
with and without epilepsy. Patients with epilepsy, however, showed
higher GADA serum titers.16 Moloney et al compared 25 patients with
T1DM and epilepsy with 36 matched pairs without epilepsy. They
found an increased rate of GADA among patients with epilepsy.17
To the best of our knowledge, studies analyzing the relationship
between GADA and epilepsy in a cohort of young patients with
T1DM and epilepsy have not been published so far as has the rela-
tionship between positive GADA and demographic, clinical, and meta-
bolic parameters among these patients.
We therefore aimed to address this question based on data of
the German/Austrian/Swiss/Luxembourgian DPV registry.
2 | RESEARCH DESIGN AND METHODS
2.1 | Data source
The multicenter, prospective, computer-based diabetes data acqui-
sition system DPV (www.d-p-v.eu) was used in this study. The DPV
initiative currently comprises 485 specialized diabetes care centers
from Germany, Austria, Switzerland, and Luxembourg using the
DPV software for standardized documentation of diabetes diagno-
sis and patient care. The electronic health record contains demo-
graphic data, type and onset of diabetes, data on metabolic control
and treatment regimen, and information on comorbidities. The
locally documented information is pseudonymized and subse-
quently transmitted twice a year to Ulm, Germany, for central ana-
lyses and quality assurance.18,19 If necessary, centers are requested
to correct inconsistent data. All plausible data are then aggregated
into a cumulative database. The DPV initiative has been approved
by the ethics committee of the University of Ulm and the
anonymized data documentation by the local review boards. Until
September 2019, demographic and clinical data of 534 756
patients with any type of diabetes were recorded in the database,
including 84 267 T1DM patients ≤20 years of age.
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2.2 | Subjects
For the present study, we considered patients with T1DM ≤ 20 years
in which GADA measurements had been documented. In this cohort,
we identified patients with comorbid epilepsy by searching the data-
base for the additional lifetime diagnosis of epilepsy using ICD-10
codes (G 40) and German search terms considering different terminol-
ogies and synonyms for epilepsy (eg, “Epilepsie,” “Anfallsleiden,”
“Krampfleiden,” “epileptische Anfälle,” “Krampfanfälle”). For the com-
parison of data, we divided the patients into four groups: Group 1:
T1DM + Epilepsy + GADA positive; Group 2: T1DM + Epilepsy
+ GADA negative; Group 3: T1DM + GADA positive; Group 4:
T1DM + GADA negative. In order to analyze the impact of GADA in
T1DM patients with epilepsy, we compared clinical and metabolic
parameters between the four groups. The final study population com-
prised 31 601 patients from 155 German, 13 Austrian, 1 Swiss, and
1 Luxembourgian centers. From the 31 601 patients with T1DM, we
identified 368 T1DM patients with comorbid epilepsy.
2.3 | Variables analyzed
For the present study, data from the most recent documented
treatment year of each patient were considered. We analyzed
demographic data (age, sex, body mass index [BMI], duration of dia-
betes [DOD], age at diabetes manifestation, as well as glycemic
control [HbA1c] and insulin dose in international units kg−1 d−1).
We used the LMS method to calculate the standard deviation score
of BMI (BMI-SDS) or BMI z-score as a measure for the degree of
overweight due to the skewness of BMI distribution based on ref-
erence data.20 Furthermore, our analysis also evaluated the rates of
documented diabetic ketoacidosis (DKA) (venous pH < 7.3 and/or
bicarbonate < 15 mM/L), severe hypoglycemia (SH) (an event
requiring assistance of another person to actively administer carbo-
hydrates, glucagon, or intravenous glucose), or hypoglycemia with
coma (HC) (loss of consciousness or occurrence of seizures) in
events per patient-year aggregated over the most recent treatment
year per patient based on Poisson regression with individual time
under risk as offset. Finally, we analyzed the frequency of addi-
tional disorders, such as celiac disease (biopsy-proven) and AIT.
To adjust for differences between laboratory methods, the multi-
ple of the mean method was applied to mathematically standardize
HbA1c measurements to the Diabetes Control and Complications
Trial (DCCT) reference range (20.7-42.6 mM/mol or 4.04%-6.05%).21
2.4 | Statistics
Data analyses were performed using SAS 9.4 (SAS Institute, Cary,
North Carolina). Logistic regression was used to analyze the relation-
ship between epilepsy and GADA with odds ratio adjusted for sex,
DOD, and age at diabetes onset (ADO). We used logistic regression
with odds ratio adjusted for DOD and ADO to calculate the
contribution of possible pathophysiologically relevant factors to the
pathogenesis of epilepsy in patients with T1DM. Hereby, we used epi-
lepsy (yes/no) as dependent variable and serum GADA titers (GADA
negative/GADA ≤ 5-fold elevated/GADA > 5-fold elevated), HbA1c
(<7.5% or ≥7.5%), DKA (yes/no), severe hypoglycemia (no severe
hypoglycemia/severe hypoglycemia/hypoglycemia with coma), sex
(male/female), celiac disease (yes/no), and AIT (yes/no) as indepen-
dent variables. Results are presented as median with quartiles or pro-
portion. We compared demographic parameters between the groups
using Wilcoxon's rank sum test for continuous and χ2-test for binary
variables. P values were corrected for multiple comparisons using the
Holm step-down method. To account for potential confounding
effects (ADO, sex, and DOD), multivariable regression models were
created to compare diabetes-related outcome variables between the
groups. Linear regression was used for continuous variables, logistic
regression for binary data, and Poisson regression for event rates.
Restricted maximum likelihood was used as estimation technique in
linear regression and maximum likelihood for logistic regression.
Results are given as adjusted means with SEM. Two-sided
P values < .05 were defined as statistically significant.
3 | RESULTS
3.1 | GADA are detected more frequently among
female patients
Three hundred sixty-eight patients with and 31 233 patients without
epilepsy were included into the analysis. Table 1 summarizes demo-
graphic data, including age at analysis, ADO, sex, and DOD dis-
tinguishing between patients with and without epilepsy as well as
patients with positive and negative GADA findings, respectively. We
found differences with regard to demographic data, particularly a
higher rate of females among GADA-positive patients (GPP).
3.2 | GADA-positive and GADA-negative patients
do not differ in their rates of epilepsy
Epilepsy was not more frequent in GPP (P = .77; odds ratio 0.97 [95%
CI 0.79-1.20]).
3.3 | GADA-positive and GADA-negative patients
with epilepsy do not differ in clinical and
metabolic data
After adjustment for ADO, sex, and DOD, we found no signifi-
cant differences between GADA-positive and GADA-negative
patients (GNP) with T1DM and epilepsy regarding BMI, BMI-
SDS, HbA1c, insulin dose, rate of DKA, rate of SH, rate of HC,
and the frequency of celiac disease and autoimmune thyroiditis
(Table 2).
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3.4 | The occurrence of SH/HC correlates with an
increased risk of epilepsy
Adjusted comparisons of parameters possibly contributing to the
pathogenesis of epilepsy between the four groups showed that SH
occurred significantly more often in GPP with epilepsy in comparison
to GPP without epilepsy (P = .04). Moreover, GNP with epilepsy had a
higher rate of HC than GPP without epilepsy (P = .01) (Table 2).
After adjusting for DOD and ADO, logistic regression did not
show any correlation between epilepsy and serum GADA titers,
HbA1c, DKA, sex, celiac disease, or AIT. HC when compared to no SH
showed a correlation with epilepsy (P < .001; odds ratio 2.73 [95% CI
1.68-4.44]).
4 | DISCUSSION
To the best of our knowledge, this is the first study analyzing the rela-
tionship between epilepsy and GADA in young patients with T1DM
and epilepsy as well as the impact of GADA on demographic, clinical,
and metabolic parameters in patients with T1DM and epilepsy. In our
cohort of patients, epilepsy was not more frequent in GPP. Therefore,
it remains unclear whether GADA are involved in the pathogenesis of
epilepsy in patients with T1DM.
Epilepsy affects 0.5% to 1% of children in the general population.
However, the validity of epilepsy diagnoses from different data
sources varies, and contemporary population-based incidence studies
are lacking.22 In our cohort of 84 267 young patients with T1DM, we
found 368 patients with comorbid epilepsy (~0.44%), that is, the inci-
dence of epilepsy in young T1DM patients would seem comparable to
that in the general population.
However, epilepsy is an umbrella term for different types of
epileptic disorders, and GADA have previously been discussed to
be associated with distinct types of epilepsy only.14 For example,
Caietta et al characterized idiopathic generalized epilepsy and non-
idiopathic temporal epilepsy as the two most common types of epi-
lepsy in their cohort of children with T1DM.23 McCorry et al com-
pared the population prevalence of T1DM in 15- to 30-year-olds to
a cohort of 518 15- to 30-year-olds with idiopathic generalized epi-
lepsy and found that the prevalence of T1DM is increased by the
factor of four in young adults with idiopathic generalized epi-
lepsy.24 Studying 233 patients with epilepsy, Errichiello et al
detected GADA in six (2.58%) patients. Two of these patients had
idiopathic generalized epilepsy and T1DM, the other four patients
had cryptogenic temporal epilepsy.25 In the DPV registry, the
type(s) of epilepsy are not documented. We therefore do not have
data on the distinct types of epilepsy in our studied cohort. Fur-
thermore, we have to keep in mind that although GADA have been
discussed to be a possible link between T1DM and epilepsy,24 up
to now, the pathomechanism and relevance of GADA in epilepsy
remain unclear, and evidence of a pathomechanistic association
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In the discussion of whether GADA are involved in the pathogen-
esis of epilepsy in patients with T1DM, we additionally have to keep
in mind that the production of GADA in T1DM patients is not always
stable, that is, during the course of T1DM, patients can change from
GADA positivity to GADA negativity and vice versa.26 Furthermore,
the possible lack of an association between GADA and epilepsy in
T1DM patients is strengthened by the fact that most patients with
GADA associated autoimmune epilepsy do not have T1DM.27
Finally, GADA-related epilepsy in T1DM might not be mediated
by GADA in the serum but by GADA in the cerebrospinal fluid (CSF).
Accordingly, children and adults with T1DM and consecutive epilepsy
have been described with high titers of GADA in the serum and
CSF.28,29 The intrathecal production of GADA could be essential for
the development of certain neurological diseases, as serum GADA are
not able to cross the blood-brain barrier.30 Interestingly, Lilleker et al
were able to observe that adult patients with epilepsy and high serum
titers of GADA had high CSF GADA titers, as well.31 Furthermore,
Aguiar et al were able to show that adult patients with T1DM and epi-
lepsy had higher serum GADA titers than T1DM patients without epi-
lepsy.16 In our study with pediatric patients with T1DM and epilepsy,
however, the degree of elevation of serum GADA titers did not corre-
late with the occurrence of epilepsy suggesting that the
pathomechanisms leading to epilepsy in patients with T1DM differ to
a certain extent between children and adults.
According to meta-analytic data,12 other pathomechanistic links
between T1DM and epilepsy than GADA must also be discussed. This
includes the metabolic abnormalities of T1DM, such as hypoglycemia
and hyperglycemia, which may damage the CNS,8 alter the balance
between the neuronal inhibition and excitation, and cause sei-
zures.32-34 In our study, HC when compared to no SH showed a corre-
lation with epilepsy. Furthermore, we were able to show that GNP
with epilepsy had a higher rate of HC than GPP without epilepsy indi-
cating that HC might be a stronger factor in the pathogenesis of epi-
lepsy in patients with T1DM than GADA. This thought is
strengthened by our observation that SH occurred significantly more
often in GPP with epilepsy in comparison to GPP without epilepsy.
Finally, both groups with epilepsy (+/− GADA) had higher mean rates
of SH with coma than both groups without epilepsy although these
differences were not statistically significant. As pointed out by Tricò
and Herzog, the acute and functional injuries induced by SH, that is,
the lack of glucose as a source of energy for brain metabolism, can
persist even after normal glucose levels are restored, leading to abnor-
malities in the electroencephalogram and perhaps to a predisposition
for unprovoked seizures.35 Therefore, repeated episodes of SH/HC in
patients with T1DM may cause neuronal damage resulting in epilepsy.
This mechanism, however, can only partially explain the relationship
between T1DM and epilepsy. As shown by Moloney et al, in 44% of
patients with T1DM and epilepsy, epilepsy precedes T1DM
suggesting that the two diseases can arise independently through par-
tially overlapping mechanisms.17 In the DPV registry, the date of epi-
lepsy diagnosis is not documented. We therefore do not have data on
which is the preceding diagnosis in our cohort of T1DM patients with
epilepsy.
Hyperglycemia, as well, is an important risk factor for focal sei-
zures in patients with T1DM, predisposing to cerebrovascular dys-
function and a secondary decrease of cerebral blood flow enhanced
by neuronal hyperosmolarity and dehydration.36 In line with these
studies, Yun and Xuefeng reported that patients with diabetes who
experienced episodes of DKA also have seizures more frequently.37
As an earlier study from the DPV registry was able to demonstrate
that the risk for DKA in pediatric patients with T1DM and epilepsy
was almost double in comparison to patients with T1DM only,38
patients with T1DM and epilepsy would seem to have the risk of
entering a vicious circle consisting of seizures and DKA. In our study,
DKA did not correlate with the occurrence of epilepsy, and the rate of
DKA did not differ between the four groups. A possible explanation
for this seeming discrepancy could be the fact that the risk for DKA is
influenced by numerous factors such as age, sex, ethnicity, personal
skills, level of diabetes education, concomitant medication, and
so on.39
Cerebrovascular damage could be another pathomechanistic link
between T1DM and epilepsy, as diabetes can result in pathological
capillary changes, leading to neurological disorders such as epilepsy.12
Hyperglycemia can induce different structural and functional damages
in blood vessels of the brain, which could result in ischemic events
and subsequent seizures secondary to impaired metabolism of endo-
thelial nitrite oxide, dysfunctions of coagulation and fibrinolytic net-
works, malfunctioning of recanalization, or increased reperfusion
injuries.40 The relevance of these mechanisms in the pathogenesis of
epilepsy in patients with T1DM, however, is controversial.36
We need to mention potential limitations of this study. The
GADA measurements were not performed centrally but in the individ-
ual laboratories associated to the respective participating centers. We
well understand the drawbacks of decentralized GADA testing but
centralized GADA measurements were not feasible for organizational
and financial reasons. Furthermore, we used serum GADA measure-
ments for our analyses, as CSF GADA measurements are not available
in the DPV registry. Finally, it has to be mentioned that a potential
limitation of a multicenter-database, such as DPV with 485 participat-
ing centers, is underreporting, that is, the possibility exists that T1DM
patients with epilepsy are not recorded due to overlooking in individ-
ual centers.
In conclusion, we found no relationship between epilepsy and
GADA in our study irrespective of serum GADA titers. We were able
to demonstrate a correlation between epilepsy and HC which is
supported by the comparisons of the rates of SH/HC between the
four groups. In our study, the impact of GADA-positive autoimmunity
in young patients with T1DM and epilepsy seems limited.
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